Table 1

Summary of the effects of the hydromorphone, 3 mg/70 kg, and saline during the first two tests of acquisition sessions (sessions 5–8) in each of eight subjects

PValues1-aMeans
DrugSessionDrug × SessionHydromorphone, 3 mg/70 kgSaline
Discrimination operant responding1-b
 Hydromorphone-appropriate.0021-c 86.0 (8.8)15.6 (9.0)
 Not hydromorphone-appropriate.00214.0 (8.8)84.5 (9.0)
Point distribution1-b
 Hydromorphone-appropriate.00185.5 (8.8)6.2 (6.5)
 Not hydromorphone-appropriate<.0019.4 (7.0)93.8 (6.5)
Discrete choice1-b
 Hydromorphone-appropriate<.00187.5 (8.6)6.2 (6.2)
 Not hydromorphone-appropriate<.00112.5 (8.6)93.8 (6.2)
VAS1-b
 Like Drug A (hydromorphone).00173.6 (9.2)2.51 (1.7)
 Like Not Drug A.00122.0 (10.1)89.0 (6.8)
 Drug Effect.009.08142.8 (8.3)3.4 (3.1)
 High.01735.5 (7.9)3.3 (3.0)
 Liking.007.06043.4 (8.2)2.8 (2.7)
 Good Effects.008.05944.0 (8.1)4.8 (3.4)
 Bad Effects0.2 (0.2)3.5 (3.5)
ARCI1-d
 MBG.0923.8 (1.5)0.0 (0.3)
 PCAG−0.2 (0.3)0.0 (0.2)
 LSD.0541.0 (0.4)0.2 (0.3)
 BG.0771.2 (0.6)−0.1 (0.3)
 Amphetamine.0501.9 (0.7)0.0 (0.3)
Adjective Rating Scales1-d
 Agonist.0195.1 (1.3)−0.6 (0.4)
 Antagonist0.1 (0.2)0.2 (0.1)
 Agonist-antagonist.0500.3 (0.2)−0.1 (0.1)
Physiological measures1-d
 Heart rate (beats/min)−4.2 (2.1)−7.8 (2.4)
 Systolic blood pressure (mm Hg)4.3 (4.7)1.7 (3.9)
 Diastolic blood pressure (mm Hg)0.8 (2.2)0.1 (2.1)
 Respiration rate (breaths/min)−0.1 (0.5)−0.2 (0.4)
 Oral temperature (°F)−0.3 (0.2)0.1 (0.2)
 Pupil diameter (mm)<.001−0.94 (0.14)0.04 (0.09)
Psychomotor/cognitive performance1-d
 DSST number correct−0.5 (0.8)−0.5 (0.7)
 DSST number trials0.17 (1.0)−0.97 (0.7)
  • 1-a  Values represent Pvalues for main effects of drug and session and drug by session interactions in a two-factor (drug and session) ANOVA.

  • 1-b  Values represent mean (S.E.) values.

  • 1-c  —, P > .10.

  • 1-d  Values represent mean (S.E.) change from predrug values.